Hansen Gwenn sold $100K of NRIX
Hansen Gwenn (Chief Scientific Officer) sold 4,111 shares of Nurix Therapeutics, Inc. (NRIX) at an average of $24.36 ($23.87–$24.64, $0.10M total) across 2 trades on 2026-08-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed event is an open-market sale of 4,111 shares at $23.8684 to $24.6415, totaling about $100,141.56, executed under a pre-arranged 10b5-1 plan.
Market read
Traders may note the insider sale for sentiment, but the 10b5-1 structure and modest dollar amount suggest limited trading edge.
What to watch
The filing does not indicate whether other insiders or the company had concurrent catalysts (earnings, trial updates, financing), so traders should not over-weight this signal.
Background
The article is an SEC Form 4 insider transaction disclosure for Nurix Therapeutics, reported by CSO Hansen Gwenn.
Ticker impact
Nurix Therapeutics Form 4 shows CSO Hansen Gwenn sold about $100.1K of NRIX shares via a 10b5-1 plan on 2026-08-04.
Likely minimal immediate price impact; any effect would be sentiment-only and small versus typical daily flows.
The filing is an open-market sale by an officer, explicitly under a pre-arranged 10b5-1 plan, and the disclosed value ($100K) is modest relative to a public biotech’s typical market capitalization.
Market effects
No clear sector read-through from a single, small 10b5-1 insider sale.
None.
None.
Counterpoint
Insider sales can still coincide with private information, but the 10b5-1 designation reduces the informational edge.
Key entities
- issuerNurix Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderHansen Gwenn
Chief Scientific Officer who executed the sale under a 10b5-1 plan.
